第29回日本遺伝子細胞治療学会学術集会
2023年9月11日〜9月13日大阪国際会議場
第29回日本遺伝子細胞治療学会学術集会
2023年9月11日〜9月13日大阪国際会議場
[SL2-1]OMNITM Triple-platform technology - Removing the barriers in CRISPR-based gene editing therapy
○David Baram1, Liat Rockah1, Milit Marom1, Shira Warszawski1, Nir Hecht1, Nir Shpak1, Rivkah Rogawski1, Shir Weber1, Veronica Moskovicz1, Bar Dagan1, Tami Khazma1, Maya Noff1, Nir Shahar1, Dotan Omer1, Roy Sirkis1, David C. Dale2, Asael Herman1, Rafi Emmanuel1, Lior Izhar1(1.EmendoBio, Inc., New York, USA, 2.Department of Medicine, University of Washington, Seattle, WA, USA)
Dr. David Baram co-founded EmendoBio and has served as its President & CEO since that time. Under his leadership, David has taken EmendoBio from the pre-seed stage through multiple financing rounds and a successful acquisition in 2020. Prior to EmendoBio, David co-founded multiple biotech companies and a seed-stage incubator in which he was responsible for technological innovation, entrepreneurship and financing. David lead the negotiation and execution of a broad range of deals including mergers & acquisitions, out-licensing, and in-licensing, fundraising over $500 million in private and public rounds, and serving as a member of the board of directors for several biotech companies. David is an inventor of over thirty patents. He completed his Ph.D. studies at the Weizmann Institute of Science under Nobel Laureate Dr. Ada Yonath.
閲覧にはパスワードが必要です
抄録パスワード認証
参加登録者の皆様へメールにてご案内しております。
参加登録者の皆様へメールにてご案内しております。